Abstract: Acrylic polymers are made by the living radical polymerization of acrylic monomers utilizing organo halide initiators with either metal-free or metal catalysts. Moreover, block copolymers of vinyl halide monomers and acrylic monomers are described by generally polymerizing either the vinyl halide monomers or acrylic monomers utilizing an organo halide initiator in the presence of either a metal catalyst or a metal-free catalyst and subsequently polymerizing thereon the remaining type of monomer.

Abstract: This invention provides a method to effectively incorporate inorganic fluorescent substance or inorganic contrast medium into latex polymer particles which are used for diagnostic test or the like, and also provides thus produced fluorescent substance-containing latex polymer particles which show decreased non-specific adsorption of protein or the like. Said latex polymer particles are produced by making latex-forming monomer, macromer which has at least a hydrophilic polymer segment and an inorganic fluorescent substance or an inorganic contrast medium co-existent simultaneously in an aqueous medium, and subjecting them to a polymerization reaction.

Abstract: It has been discovered that using n-butylmethyldimethoxysilane (BMDS) as an external electron donor for Ziegler-Natta catalysts can provide a catalyst system that may prepare polypropylene films with improved properties. The catalyst systems of the invention provide for controlled chain defects/defect distribution and thus a regulated microtacticity. Consequently, the curve of storage modulus (G?) v. temperature is shifted such that the film achieves the same storage modulus at a lower temperature enabling faster throughput of polypropylene film through a high-speed tenter.

Abstract: A process for preparing a polyamide by reacting a mixture which comprises a monomer which has a nitrile group and has at least one other functional group capable of forming a carboxamide group, and comprises water, in the presence of titanium dioxide as catalyst, which comprises using titanium dioxide whose BET surface area, determined to the German standard DIN 66 131 volumetrically by the multipoint method, is in the range from 5 to 35 m2/g.

Abstract: A method for removing contaminants from synthetic resin material containers using a first organic solvent system and a second carbon dioxide system. The organic solvent is utilized for removing the contaminants from the synthetic resin material and the carbon dioxide is used to separate any residual organic solvent from the synthetic resin material.

Abstract: Ultrapure olefinic polymeric articles of manufacture can be prepared by a process comprising: providing olefinic polymeric material containing impurities, subjecting the olefinic polymeric material to supercritical CO2 at a pressure of at least about 4000 psi (281.23 kg/cm2) at a temperature of from about 35° C. and above, to extract the impurities from the olefinic polymeric material and produce ultrapure olefinic polymeric material, and molding ultrapure articles of manufacture from the ultrapure, olefinic polymeric material.

Abstract: To provide a novel polyhydroxyalkanoate having a reactive functional group in a molecule and a method of producing the same; and a novel polyhydroxyalkanoate having a new function obtained by chemically modifying the polyhydroxyalkanoate having a reactive functional group and a method of producing the same. By utilizing a vinyl group of a polyhydroxyalkanoate containing a unit having the vinyl group at a side chain thereof, a polyhydroxyalkanoate containing units having a carboxyl group, an amide group, and a sulfonic group in a molecule is induced.

Abstract: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.

Abstract: A nucleotide sequence encoding a malic enzyme and a method for preparing succinic acid using the same, more particularly, a maeB nucleotide sequence encoding a malic enzyme B having the activity of converting pyruvic acid or pyruvate to malic acid or malate, or vice versa, a recombinant vector containing the gene, a microorganism transformed with the recombinant vector, and a method for preparing succinic acid using the transformed microorganism.

Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Abstract: The present invention provides antibodies (e.g., monoclonal antibodies) that specifically binds to mammalian IgE (e.g., dog IgE). In some embodiments the antibodies bind to an epitope between amino acids 145-166 of mammalian IgE; in other embodiments the antibodies bind to an epitope between amino acids 356-374 of mammalian IgE. The antibodies may be used for allergen reactivity testing in human subjects or animal subjects for veterinary purposes.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.

Abstract: Compounds, compositions and methods for treating conditions characterized by leukocyte rolling are described. The compounds contain glycosulfopeptide structures comprising sulfated tyrosines and sialyated, fucosylated N-acetyllactosamino glycans. The glycosulfopeptides may be conjugated or complexed to other compounds for enhancing serum half-life or for controlled release, for example. Examples of conditions treated include inflammation, ischemia-reperfusion injury, rheumatoid arthritis, atherosclerosis, leukocyte-mediated lung injury, restenosis, and thrombosis.

Abstract: Embodiments of the invention include compositions comprising and methods utilizing a retroviral integrase complex comprising a recombinant integrase having a domain comprising a non-native protein binding site, and a DNA binding protein comprising a DNA binding domain and a peptide binding domain that binds the non-native protein binding site of the recombinant integrase.

Abstract: The present invention relates to a method for the extraction of proteins, protein fragments and/or peptides from biological samples, where the extractants employed are ionic liquids of the general formula K+A?, to a kit for the extraction of proteins, protein fragments and/or peptides, and to the use thereof.

Abstract: The present invention is directed generally to recombinant methods for making a desired pegylated protein and pooling of same. The method(s) yield a polypeptide product containing reduced levels of aggregate thereof pooled to provide the desired pegylated isoforms thereof.

Abstract: The present invention relates to dyes of formula (1) that are soluble in organic solvents, wherein Cat+ is an organic cation, to a process for their preparation and to their use in the production of colored plastics or polymeric color particles, printing colorants, printing pastes and printing inks.

Abstract: The invention concerns a composition containing stabilised particles of cationic transfection agent(s)/nucleic acid complexes characterised in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.

Abstract: CASB618 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB618 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases, and related conditions.

Abstract: Novel compounds are provided which are useful as linking groups in chemical synthesis, preferably in the solid phase synthesis of oligonucleotides and polypeptides. These compounds are generally photolabile and comprise protecting groups which can be removed by photolysis to unmask a reactive group. The protecting group has the general formula Ar—C(R1)(R2)—O—C(O)-wherein: Ar is an optionally substituted fused polycyclic aryl or heteroaromatic group or a vinylogous derivative thereof; R1 and R2 are independently H, optionally substituted alkyl, alkenyl or alkynyl, optionally substituted aryl or optionally substituted heteroaromatic, or a vinylogous derivative of the foregoing; and X is a leaving group, a chemical fragment linked to Ar—C(R1)(R2)—O—C(O)— via a heteroatom, or a solid support; provided that when Ar is 1-pyrenyl and R1 and R2 are H, X is not linked to Ar—C(R1)(R2)—O—C(O)— via a nitrogen atom.

Abstract: 2-Chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine is synthesized by reacting a 2-chloro-6-substituted purine with a protected and activated 2-deoxy-2-fluoro-D-arabinofiranose; and reacting with a base such as ammonia to provide 2-chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine. When the purine reactant is substituted in the 6 position with a halogen, a reaction step with an alkoxide is carried out prior to the reaction with ammonia.

Abstract: A method of making chlorins comprises the steps of reacting (e.g. condensing) a dipyrrin western half intermediate with an eastern half intermediate to form a tetrahydrobilene, and then cyclizing the tetrahydrobilene to form a chlorin. Intermediates including tetrahydrobilenes useful in such reactions are also described.

Abstract: An improved process for preparation of ceftriaxone sodium of formula (II), is disclosed.

Abstract: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

Abstract: The invention provides compounds of formula I: wherein Y is F, Cl or Br; or a pharmaceutically acceptable salt thereof. The compounds are effective antitumor agents. The invention also provides pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering a compound of formula I or a salt thereof to a mammal in need thereof.

Abstract: Anhydrous crystalline fexofenadine hydrochloride Form C, crystalline fexofenadine acetate monohydrate Form D, crystalline fexofenadine acetate dihydrate Form E and crystalline fexofenadine free base monohydrate Form F, processes of preparing the same, pharmaceutical compositions thereof, therapeutic uses thereof and methods of treatment therewith.

Abstract: Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula.

Abstract: The invention relates to novel processes for the preparation of high-purity roflumilast.

Abstract: The present invention provides a synthesis for the preparation of epothilone derivatives of formula 9 wherein R1 is methyl, and R2 is an unsubstituted or substituted aryl; an unsubstituted or substituted heteroaryl; or an unsubstituted or substituted heterocyclic radical fused to a benzene nucleus; and salts thereof, and intermediates for the synthesis of a compound of formula 9.

Abstract: This invention relates to novel thiazole(bi)cycloalkylcarboxanilides of the formula (I) in which Q and R1 are as defined in the disclosure, to a process for preparing these compounds and to their use for controlling unwanted microorganisms.

Abstract: Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.

Abstract: Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.

Abstract: Disclosed herein is a method for producing a 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine. The method comprises forming a reaction mixture comprising at least one substituted or unsubstituted phenolphthalein compound, at least one substituted or unsubstituted primary hydrocarbyl amine, and an acid catalyst; and heating the reaction mixture to form 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine. An adduct of the 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine is formed either by using an excess of the primary hydrocarbyl amine in the first heating step, or by isolating crude 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine after the heating step and then reacting with a further amount of the primary hydrocarbyl amine. The 2-hydrocarbyl-3,3-bis(4-hydroxyaryl)phthalimidine has a formula: where R1 is selected from the group consisting of a hydrogen and a hydrocarbyl group, and R2 is selected from the group consisting of a hydrogen, a hydrocarbyl group, and a halogen.

Abstract: Disclosed are fused cyclic compounds, method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds of formula Also disclosed are fused heterocyclic imido and amido compounds of formula and stereoisomers thereof. The groups G, L, Z1, Z2, Q1, Q2, A1, A2, Y?, and W? are defined herein.

Abstract: 7,8-Bicyclic-chroman derivatives of Formula I: wherein the substituents are defined as in the specification or the pharmaceutically acceptable salts thereof, are disclosed. They are useful for the treatment of inflammatory disorders, neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.

Abstract: Compounds of formula I are provided: wherein each of R1, R2, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of melatoninergic receptors. The compounds, and compositions containing the compounds, can be used to treat melatoninergic disorders.

Abstract: Catalysts useful for epoxidizing olefins are disclosed. The catalysts comprise a vinylpyridine polymer and a titanium zeolite. Preferably, the vinylpyridine polymer encapsulates the titanium zeolite. The catalysts are easy to prepare and use, they are easy to recover and reuse, and they convert olefins to epoxides in good yields with high selectivity. Surprisingly, ring-opening reactions that form glycol or glycol ether by-products are minimized by using the vinylpyridine polymer-containing catalysts. The catalysts are valuable for making propylene oxide from propylene and hydrogen peroxide. Vinylpyridine polymer-encapsulated transition metals and their use to produce hydrogen peroxide from hydrogen and oxygen is also disclosed.

Abstract: Catalyst mixtures useful for the direct epoxidation of olefins are disclosed. The catalyst mixture comprises a titanium or vanadium zeolite and a supported catalyst comprising a noble metal, bismuth, and a carrier. The invention includes a process for producing an epoxide comprising reacting an olefin, hydrogen and oxygen in the presence of the catalyst mixture. The process results in significantly reduced alkane byproduct formed by the hydrogenation of olefin.

Abstract: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. Also, the invention encompasses compounds of the formula: A-X-Y-Z-R1 wherein A is a carboxy group or is absent; X is a polyol, Y is —C(?O)—, —C(?S)—, or is absent; Z is O, S, or NH; and R1 is a polyether, wherein one or more hydroxy groups of the polyol are acylated with a fatty acid residue, wherein the compounds form micelle assemblies. The invention encompasses methods of encapsulating molecules using the compounds of the invention.

Abstract: The present invention relates to a compound which is flexibly amenable to the alteration, without impairing its photosensitivity, of its structural moiety which affects film forming ability and the resulting surface properties, the compound being capable of undergoing surface alteration by irradiation with relatively low energy wavelength, and of forming an organic thin film on a substrate with good reproducibility, and an organic thin film formed body, the compound being represented by formula (1). (In the formula, X represents a heteroatom-containing functional group capable of interacting with a surface of a metal or a metallic oxide, R represents a C1 to C20 alkyl group, a C1 to C20 alkoxy group, an aryl group, or a C1 to C20 alkoxycarbonyl group; n represents an integer of 1 to 30, and m represents an integer of 0 to 5; G1 represents a single bond or a bivalent hydrocarbon radical having carbon atoms of 1 to 3; Ar represents an aromatic group which may have a substituent; G2 represents O, S, or Nr.

Abstract: An organopolysiloxane composition comprising an organopolysiloxane, an organosilicon compound having at least three hydrolyzable radicals in the molecule, an acid anhydride and optionally a filler cures at room temperature and exhibits excellent adherence to magnesium alloys.

Abstract: A process of hydrocyanation of diolefins such as butadiene is carried out in the presence of a catalytic system comprising a transition metal and mono- and pluri-dentate organophosphorus ligands. The reaction medium containing branched nitrites subsequently is isomerized in the absence of hydrogen cyanide.

Abstract: A process for the industrial synthesis of the compound of formula (I) Application in the synthesis of agomelatine.

Abstract: A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

Abstract: A process for producing a fluorine-containing acrylic acid ester represented by CH2?C(Rf)(COOR) characterized in that 1-bromo-1-perfluoroalkylethene represented by CH2?CBr—Rf, or 1,2-dibromo-1-perfluoroalkylethane represented by CH2CBr—CHBr—Rf is allowed to react with an alcohol represented by ROH in the presence of a palladium catalyst, carbon monoxide, and two or more kinds of bases. The fluorine-containing acrylic acid ester is a useful compound having wide applications in materials for pharmaceuticals and functional polymers.

Abstract: The present invention relates to a novel process for the production of [2-(4-fluoro-benzyl)-phenyl]-acetic acid, a compound obtainable from phthalic anhydride. The process comprises the subsequent steps a) through e): a) reacting phthalic anhydride with fluorobenzene or a derivative thereof in appropriate reaction conditions; b) over reducing the product obtained in step a) at the ketone moiety; c) reducing the product obtained in step b) with sodium dihydro-bis(2-methoxyethoxy)aluminate (Red-Al) to the corresponding alcohol; d) chlorinating the alcohol obtained in step c); e) inserting CO into the product obtained in step d) through an appropriate Pd-containing catalytic system. In an alternative embodiment, the step e) is replaced by the steps f1) and f2): f1) reacting the product obtained in step d) with sodium cyanide; f2) hydrolysing the product obtained in step f1).

Abstract: Novel C3-C19 alkyl- and aryl-thiotrifluoroacetates are provided which have the structure wherein Q is C9-C19 alkyl or aryl, and are useful protecting agents for the amino or hydroxy functional groups of amines, amino acids or primary or secondary alcohols or amino alcohols to enable formation of amide bonds in peptides or proteins which are useful as screening agents, pharmaceuticals and cosmetics. A process for preparing C3-C19 alkyl- and aryl-thiotrifluoroacetates is also provided wherein a C3-C19 alkylthiol or arylthiol is treated with trifluoroacetic anhydride (TFAA) in the presence of organic base such as pyridine, a solvent such as dichloromethane (DCM) and dimethylaminopyridine (DMAP) as a catalyst to form the desired C3-C19 alkyl- or aryl-thiotrifluoroacetate.

Abstract: An integrated process for making methanol, acetic acid, and a product from an associated process is disclosed. Syngas (120) is produced by combined steam reforming (109) and autothermal reforming (118) of natural gas (102) where a portion (112) of the natural gas bypasses the steam reformer (109) and is blended with the steam reformer effluent for supply to the autothermal reformer (ATR) (118) with CO2 recycle (110). A portion of the syngas is fed to CO2 removal (122) to obtain the recycle CO2 and cold box (130) to obtain a hydrogen stream (131) and a CO stream (135). The remaining syngas, hydrogen stream (131) and CO2 from an associated process are fed to methanol synthesis (140), which produces methanol and a purge stream (124) supplied to the CO2 removal unit. The methanol is supplied to an acetic acid unit (13)6 with the CO (135) to make acetic acid, which in turn is supplied to a VAM synthesis unit (148).